Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children

Objective: Our aim was to study the clinical efficacy of pneumococcal conjugate 13-valent vaccine (PCV13) in children aged less than 3 years.Methods: retrospective comparative study of the incidence of acute respiratory infections (ARI), otitis and pneumonia during the first three years of life in 1...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Педиатрическая фармакология
المؤلفون الرئيسيون:	S. M. Kharit, I. V. Fridman, A. N. Pavlyukova, E. Ya. Frolova, A. A. Ruleva
التنسيق:	مقال
اللغة:	الروسية
منشور في:	Union of pediatricians of Russia 2016-12-01
الموضوعات:	children pneumococcal infection vaccination conjugated 13-valent vaccine acute respiratory infection otitis pneumonia
الوصول للمادة أونلاين:	https://www.pedpharma.ru/jour/article/view/1462

مواد مشابهة

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
حسب: Germaine Hanquet, وآخرون
منشور في: (2022-01-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
حسب: M. V. Fedoseenko, وآخرون
منشور في: (2014-09-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
حسب: Ching-Fen Shen, وآخرون
منشور في: (2021-09-01)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
حسب: N. L. Chernaya, وآخرون
منشور في: (2013-01-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
حسب: A. V. Rudakova, وآخرون
منشور في: (2014-09-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
حسب: A. V. Rudakova, وآخرون
منشور في: (2014-01-01)

Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan
حسب: Erika Kurihara, وآخرون
منشور في: (2022-04-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
حسب: Hye-Young Kim, وآخرون
منشور في: (2021-03-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
حسب: Jeffrey Vietri, وآخرون
منشور في: (2020-01-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
حسب: Andrew D. Wiese, وآخرون
منشور في: (2016-06-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
حسب: Matthew Wasserman, وآخرون
منشور في: (2019-03-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
حسب: A. L. Perova, وآخرون
منشور في: (2014-09-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
حسب: John M. McLaughlin, وآخرون
منشور في: (2019-04-01)

Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
حسب: Murat Sütçü, وآخرون
منشور في: (2017-02-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
حسب: Thundon Ngamprasertchai, وآخرون
منشور في: (2023-06-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
حسب: Mikkelsen Malene B, وآخرون
منشور في: (2023-08-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
حسب: N. L. Chernaya, وآخرون
منشور في: (2012-02-01)

Effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine on community-acquired pneumonia: a retrospective cohort study among young children in Suzhou city
حسب: Zhao-jin LI, وآخرون
منشور في: (2022-11-01)

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
حسب: Satoshi Nakano, وآخرون
منشور في: (2020-11-01)

Analysis of the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar
حسب: S. A. Pyrkova, وآخرون
منشور في: (2019-10-01)

Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
حسب: Caixia Wang, وآخرون
منشور في: (2021-07-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
حسب: Beate Schmoele-Thoma, وآخرون
منشور في: (2019-03-01)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
حسب: Christine Juergens, وآخرون
منشور في: (2018-08-01)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
حسب: Daria D. Vankova, وآخرون
منشور في: (2018-10-01)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
حسب: Margarita A. Soloshenko, وآخرون
منشور في: (2017-10-01)

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population
حسب: Stéphane Fiévez, وآخرون
منشور في: (2025-08-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
حسب: Melina Gade Sikjær, وآخرون
منشور في: (2023-01-01)

A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine
حسب: Idrissa Diawara, وآخرون
منشور في: (2017-04-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
حسب: Ekaterina I. Alekseeva, وآخرون
منشور في: (2019-09-01)

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
حسب: YANG Shoufei, وآخرون
منشور في: (2022-08-01)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
حسب: Wenjuan Wang, وآخرون
منشور في: (2022-01-01)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
حسب: Xinren Che, وآخرون
منشور في: (2023-05-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
حسب: Kristiana Alexandrova Nikolova, وآخرون
منشور في: (2021-10-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
حسب: Yu Hu, وآخرون
منشور في: (2022-01-01)

Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003–2022
حسب: Yasiini Nuwamanya, وآخرون
منشور في: (2024-10-01)

A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
حسب: Ting-An Yen, وآخرون
منشور في: (2025-02-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
حسب: Sophie Warren, وآخرون
منشور في: (2023-08-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
حسب: V. K. Tatochenko, وآخرون
منشور في: (2012-03-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
حسب: Earnshaw Stephanie R, وآخرون
منشور في: (2012-04-01)

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
حسب: Bhagirath B. Solanki, وآخرون
منشور في: (2017-09-01)